SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Decrease in Short Interest

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 7,460,000 shares, a drop of 17.6% from the November 30th total of 9,050,000 shares. Based on an average daily volume of 978,800 shares, the days-to-cover ratio is currently 7.6 days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SLS. Virtu Financial LLC increased its holdings in SELLAS Life Sciences Group by 24.1% in the 3rd quarter. Virtu Financial LLC now owns 79,241 shares of the company’s stock valued at $99,000 after purchasing an additional 15,398 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of SELLAS Life Sciences Group by 17.1% in the third quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock worth $757,000 after buying an additional 88,183 shares during the period. Anson Funds Management LP acquired a new stake in shares of SELLAS Life Sciences Group in the third quarter valued at about $992,000. XTX Topco Ltd purchased a new stake in shares of SELLAS Life Sciences Group during the 3rd quarter valued at about $78,000. Finally, State Street Corp raised its holdings in shares of SELLAS Life Sciences Group by 30.2% during the 3rd quarter. State Street Corp now owns 174,529 shares of the company’s stock valued at $218,000 after buying an additional 40,500 shares during the period. 17.38% of the stock is owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Stock Performance

SELLAS Life Sciences Group stock traded down $0.03 during midday trading on Friday, reaching $0.98. The stock had a trading volume of 1,076,535 shares, compared to its average volume of 1,116,367. The stock’s 50-day simple moving average is $1.12 and its 200 day simple moving average is $1.19. SELLAS Life Sciences Group has a twelve month low of $0.50 and a twelve month high of $1.72. The stock has a market capitalization of $68.97 million, a PE ratio of -1.42 and a beta of 2.39.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.